GATM Polymorphism Associated with the Risk for Statin-Induced Myopathy Does Not Replicate in Case-Control Analysis of 715 Dyslipidemic Individuals  by Luzum, Jasmine A. et al.
Short ArticleGATM Polymorphism Associated with the Risk for
Statin-Induced Myopathy Does Not Replicate in
Case-Control Analysis of 715 Dyslipidemic
IndividualsGraphical AbstractHighlightsd The association of GATM rs9806699 with statin-induced
myopathy was not replicated
d GATM rs9806699 allele/genotype frequencies were similar in
SIM cases and controls
d Meta-analysis yielded a marginal, but null, association of
GATM rs9806699 with SIMLuzum et al., 2015, Cell Metabolism 21, 622–627
April 7, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.03.003Authors
Jasmine A. Luzum,
Joseph P. Kitzmiller, ...,
Heather M. Ochs-Balcom,
Georgirene D. Vladutiu
Correspondence
luzum.2@osu.edu
In Brief
Statin-induced myopathy (SIM) is the
most common reason for discontinuation
of statin therapy. While a polymorphism
affecting the gene encoding glycine
amidinotransferase (GATM rs9806699)
was previously associated with reduced
SIM, Luzum et al. do not replicate this
association in a large, multicenter SIM
case-control study including 715
individuals.
Cell Metabolism
Short ArticleGATM Polymorphism Associated with the Risk
for Statin-Induced Myopathy Does Not Replicate in
Case-Control Analysis of 715 Dyslipidemic Individuals
Jasmine A. Luzum,1,8,* Joseph P. Kitzmiller,1,8 Paul J. Isackson,2 Changxing Ma,3 Marisa W. Medina,4 Anees M. Dauki,1,5
Eduard B. Mikulik,1 Heather M. Ochs-Balcom,6,9 and Georgirene D. Vladutiu7,9
1Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2Department of Pediatrics
3Department of Biostatistics
University at Buffalo, Buffalo, NY 14214, USA
4Children’s Hospital Oakland Research Institute, Oakland, CA 94609, USA
5Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
6Department of Epidemiology and Environmental Health
7Departments of Pediatrics, Neurology, and Pathology and Anatomical Sciences
University at Buffalo, Buffalo, NY 14214, USA
8Co-first author
9Co-senior author
*Correspondence: luzum.2@osu.edu
http://dx.doi.org/10.1016/j.cmet.2015.03.003SUMMARY
Statin-induced myopathy (SIM) is the most common
reason for discontinuation of statin therapy. A poly-
morphism affecting the gene encoding glycine
amidinotransferase (GATM rs9806699 G > A) was
previously associated with reduced risk for SIM.
Our objective was to replicate the GATM association
in a large, multicenter SIM case-control study. Mild
and severe SIM cases and age- and gender-matched
controls were enrolled. Participants were genotyped,
and associations were tested (n = 715) using chi-
square and logistic regression with consideration
for SIM severity and exclusion of subjects with
potentially confounding comedications. The minor
allele (A) frequencies of GATM rs9806699 in the
controls (n = 106), mild SIM (n = 324), and severe
SIM (n = 285) caseswere 0.26, 0.28, and 0.29, respec-
tively (p = 0.447). The unadjusted odds ratio for the
A allele for any SIM (mild or severe) was 1.14 (0.82–
1.61; p = 0.437), which remained nonsignificant in
all models. Our results do not replicate the associa-
tion between GATM rs9806699 and SIM.
INTRODUCTION
Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors, are highly effective in reducing the risk
for major cardiovascular events. The most common reason
Americans discontinue their statin therapy is muscle-related
side effects (Cohen et al., 2012), or statin-induced myopathy
(SIM). SIM can range in severity from mild, tolerable symptoms
to life-threatening rhabdomyolysis. Rhabdomyolysis is rare622 Cell Metabolism 21, 622–627, April 7, 2015 ª2015 Elsevier Inc.(%0.1% frequency), but SIM has been reported by up to 25%
and 60% of current and former statin users, respectively (Cohen
et al., 2012). Until the factors for predicting SIM are character-
ized, patients will continue to experience SIM at unacceptably
high rates or experience unnecessary cardiovascular events
(as a result of discontinuation of their statin therapy) (McGinnis
et al., 2009; Simpson and Mendys, 2010; The West of Scotland
Coronary Prevention Study Group, 1997).
Mangravite et al. (2013) recently reported a potential genetic
marker for decreased risk of SIM. Using gene expression
profiling of lymphoblastoid cell lines (LCLs), they identified an
interaction between a cis-eQTL for the glycine amidinotransfer-
ase gene (GATM; rs9806699; G > A) and simvastatin exposure
(Mangravite et al., 2013). Glycine amidinotransferase is the
rate-limiting enzyme required for creatine biosynthesis. Creatine
is predominantly synthesized in the liver and kidneys and is
subsequently transported to skeletal muscle, providing an
important source of cellular energy. The A allele was associated
with a greater decrease inGATMRNA expression in simvastatin-
exposed LCLs compared to nonexposed control LCLs. Mangra-
vite et al. (2013) subsequently translated these in vitro findings,
investigating the effect of the GATM rs9806699 G > A polymor-
phism in two independent clinical studies (total SIM cases n =
172). The A allele was significantly associated with decreased
risk of SIM (meta-analysis odds ratio = 0.60; 95% confidence
interval = 0.45–0.81; p = 6 3 104). Mangravite et al. (2013)
hypothesized that the observed protective effect of the A allele
results from the attenuation of the cellular processes necessary
for SIM development, and the attenuation results from the dimin-
ished myocellular capacity to store energy as phosphocreatine
(as a result of decreased creatine availability) associated with
theGATMA allele. In a previous issue ofCell Metabolism, Ballard
and Thompson (2013) detail and explore the mechanism pro-
posed by Mangravite et al. (2013), concluding that additional
investigation is necessary in order to determine the significance
of GATM rs9806699 in the development of SIM. A protective
effect of GATM rs9806699 was not identified in a prior genome-
wide association study (GWAS) (Link et al., 2008), and further-
more, GATM deficiency has been identified as a contributing
factor of myopathy (Edvardson et al., 2010).
Two replication studies byCarr et al. (2014) (n = 150SIMcases)
and Floyd et al. (2014) (n = 175 SIM cases) did not replicate the
association reported by Mangravite et al. (2013). Carr et al.
(2014) reported an odds ratio = 0.94 (p = 0.68), and Floyd et al.
(2014) reported an odds ratio = 0.84 (95% CI = 0.52–1.36; p =
0.49; excluding fibrate users) for the GATM rs9806699 A allele.
Fixed-effect meta-analyses by Floyd et al. (2014) andMangravite
et al. (2014) both yielded null associations for rs9806699. The
following hypotheses have been proposed to explain the failed
replications of the GATM rs9806699 association with SIM: (1)
low power to detect a modest effect size; (2) the A allele is only
protective against mild SIM; (3) the association is masked by
confounding comedications; and (4) patient heterogeneity. An
adequately powered study of well-characterized SIM cases is
necessary for a more definitive understanding of the clinical
validity of GATM rs9806699 in SIM. Herein we address the hy-
potheses for failed replication of GATM rs9806699 and SIM in
ourown replication study, usinga large,multicenter, independent
case-control study that includes both mild and severe SIM.
RESULTS
A total of 836 participants were enrolled in this multicenter,
case-control study of SIM. Controls were treated with statin
therapy for at least 12 months without myopathic symptoms.
To enter the study, the participants could have been physician
referred (53%) or self referred (47%), but the SIM phenotype
was evaluated via the same questionnaire in all participants,
regardless of the mode of study entry. Caucasian participants
with known statin treatment and GATM rs9806699 genotype
were included in the analysis (n = 715). Analysis of other racial/
ethnic groups was underpowered due to small sample sizes
(n < 50 in each non-Caucasian racial/ethnic group). The GATM
rs9806699 polymorphism was in Hardy-Weinberg equilibrium
in the Caucasian subjects (p = 0.270). Participant characteristics
stratified by GATM rs9806699 genotypes and SIM status are
displayed in Table 1. The differences in the characteristics and
sample sizes between the cases and controls were eliminated
in a propensity-matched data set (see Table S1 available online).
The GATM rs9806699 minor allele and genotype frequencies in
the controls, mild SIM, and severe SIM cases are displayed
and compared in Table 2. No significant differences in GATM
rs9806699 allele or genotype frequencies were found in the
complete analytical data set (n = 715) in the subgroup of subjects
without potentially confounding comedications (n = 386) or in the
propensity-matched data set (n = 188). The GATM rs9806699
polymorphism was not significantly associated with SIM
(mild and severe combined), mild SIM alone, or severe SIM
alone in the complete analytical data set (n = 715), the limited
data set of subjects without potentially confounding comedi-
cations (n = 386), or the propensity-matched data set (n = 188)
(Table 3). A summary of all studies investigating the association
between GATM variants and SIM is displayed in the Table S2,
and the results for a fixed-effects meta-analysis for rs9806699
are presented in Figure 1. The meta-analysis yielded a marginal,Cbut still null, association between GATM rs9806699 and SIM:
odds ratio = 0.82 (95% CI = 0.66–1.02; p = 0.072).
DISCUSSION
The protective effect of GATM rs9806699 G > A reported by
Mangravite et al. (2013) was not replicated in our case-control
analyses of SIM in 715 Caucasians. Our null findings are con-
sistent with those reported in two other recent studies by Carr
et al. (2014) and Floyd et al. (2014). Furthermore, our analysis
addressed several of the limitations that were proposed as caus-
ative for the previously failed replications. Our study has the
largest number of SIM cases (n = 609) among the previously
reported association studies (n = 175 was largest number of
SIM cases in the study by Floyd et al. [2014]) and sufficient power
to detect at least a 25% reduction in the risk of SIM with GATM
rs9806699 (i.e., 80% power to detect an odds ratio %0.75 in
our overall sample) (Demidenko, 2007). We tested specifically
whether the A allele was protective against mild SIM, severe
SIM, or both groups combined. We performed analyses limited
to a subgroup of participants without potentially confounding
comedications, and in a propensity-matched data set in which
differences in characteristics and sample sizes between cases
and controls were eliminated. In all of these analyses, the associ-
ationbetweenGATM rs9806699 andSIM reportedbyMangravite
et al. (2013)wasnotobserved.Notably, adirect comparisonof the
patient characteristics in our study to the Mangravite et al. (2013)
study is not possible with the available published data. A few
patient characteristics can be found in the original Marshfield
(Mareeduet al., 2009) andSEARCH (Linket al., 2008) publications
for the overall patient samples, but the characteristics of the sub-
groups used specifically in the Mangravite et al. (2013) analysis
are unavailable. However, some notable differences between
our study and the overall Marshfield andSEARCHstudies include
the statin treatment (our study is the only one to include rosuvas-
tatin) and gender (the SEARCH trial was 83%male).
Adding our data to the previous data by Mangravite et al.
(2013), Carr et al. (2014), and Floyd et al. (2014) to a fixed-effect
meta-analysis still yielded a null association, although it tended
toward significance (p = 0.072). Notably, the Mangravite et al.
(2013) data from the SEARCH trial could not be included in our
meta-analysis because rs9806699 was not genotyped. Other
variants in GATM in linkage disequilibrium with rs9806699
(rs1719247 and rs1346268) were statistically significant in the
SEARCH trial. Because our meta-analysis tended toward sig-
nificance, it is possible that the addition of the SEARCH trial
data to a meta-analysis (if SEARCH had genotyped rs9806699)
could have yielded a significant association. Therefore the A
allele may have a small protective effect in a limited population
of patients not treated with confounding comedications, but
further studies are needed to determine the clinical relevance
of that scenario.
Patient phenotypic heterogeneity among studies of GATM
rs9806699 and SIM (and SIM studies in general) is a major issue.
SIM symptoms can include muscle pain, tenderness, stiffness,
cramping, weakness, and/or fatigue. Patients often present
with muscle symptoms but without creatine kinase (CK) eleva-
tions or present with CK elevations and no muscle symptoms
(Baker and Samjoo, 2008). No widely accepted standardell Metabolism 21, 622–627, April 7, 2015 ª2015 Elsevier Inc. 623
Table 1. Participant Characteristics Overall and Stratified by GATM rs9806699 G > A Genotype and SIM Status
Cases (n = 609; 85%) Controls (n = 106; 15%)
Characteristic All (n = 715) A/A
(n = 43; 6%)
A/G
(n = 261; 37%)
G/G
(n = 305; 43%)
A/A
(n = 7; 1%)
A/G
(n = 41; 6%)
G/G
(n = 58; 8%)
p valuea
Male gender 374 (52%) 22 (51%) 134 (51%) 170 (56%) 4 (57%) 18 (44%) 26 (46%) 0.615
Age (years) 58 (11) 58 (15) 58 (16) 58 (15) 64 (13) 61 (13) 60 (17) 0.686
Atorvastatin dose
equivalents (mg)b
20 (10) 20 (30) 10 (30) 20 (10) 15 (30) 10 (20) 10 (10) 0.374
Atorvastatin 392 (55%) 26 (60%) 144 (55%) 148 (49%) 4 (57%) 27 (66%) 43 (74%) 0.006
Simvastatin 143 (20%) 4 (9%) 53 (20%) 75 (25%) 2 (29%) 6 (15%) 3 (5%)
Rosuvastatin 83 (12%) 10 (23%) 29 (11%) 39 (13%) 0 (0%) 2 (5%) 3 (5%)
Pravastatin 52 (7%) 1 (2%) 20 (8%) 24 (8%) 0 (0%) 2 (5%) 5 (9%)
Lovastatin 30 (4%) 0 (0%) 11 (4%) 13 (4%) 0 (0%) 4 (10%) 2 (3%)
Other statin 15 (2%) 2 (5%) 4 (2%) 6 (2%) 1 (14%) 0 (0%) 2 (3%)
Coronary artery disease 137 (19%) 8 (19%) 57 (22%) 64 (21%) 1 (14%) 3 (7%) 4 (7%) 0.045
Myocardial infarction 97 (14%) 6 (14%) 39 (15%) 44 (14%) 2 (29%) 5 (12%) 2 (3%) 0.219
Diabetes 109 (15%) 8 (19%) 41 (16%) 48 (16%) 2 (29%) 4 (10%) 6 (10%) 0.628
Hypertension 338 (47%) 24 (56%) 130 (50%) 154 (50%) 2 (29%) 10 (24%) 17 (29%) 0.001
Smoker 245 (34%) 19 (44%) 104 (40%) 103 (34%) 2 (29%) 7 (17%) 9 (16%) 0.001
Family history of
heart disease
345 (48%) 21 (49%) 138 (53%) 164 (54%) 3 (43%) 9 (22%) 10 (17%) <0.001
Family history of
muscle disease
42 (6%) 4 (9%) 18 (7%) 16 (5%) 0 (0%) 1 (2%) 3 (5%) 0.758
Metabolic muscle
disease
19 (3%) 3 (7%) 5 (2%) 11 (4%) 0 (0%) 0 (0%) 0 (0%) 0.217
Inflammatory muscle
disease
55 (8%) 3 (7%) 25 (10%) 26 (9%) 0 (0%) 0 (0%) 1 (2%) 0.114
Hypothyroidism 91 (13%) 3 (7%) 41 (16%) 40 (13%) 0 (0%) 3 (7%) 4 (7%) 0.200
Heavy alcohol
consumption
17 (2%) 1 (2%) 8 (3%) 8 (3%) 0 (0%) 0 (0%) 0 (0%) 0.768
Obesity 122 (17%) 11 (26%) 52 (20%) 54 (18%) 0 (0%) 3 (7%) 2 (3%) 0.008
Liver disease 17 (2%) 0 (0%) 11 (4%) 6 (2%) 0 (0%) 0 (0%) 0 (0%) 0.326
Kidney disease 14 (2%) 1 (2%) 7 (3%) 5 (2%) 0 (0%) 0 (0%) 1 (2%) 0.881
Participants taking
R1 comedication(s)
that could independently
cause myopathyc
34 (5%) 2 (5%) 13 (5%) 18 (6%) 0 (0%) 1 (2%) 0 (0%) 0.480
Participants takingR1
comedication(s) that
could treat SIMc
260 (36%) 21 (49%) 114 (44%) 109 (36%) 0 (0%) 7 (17%) 9 (16%) <0.001
Participants takingR1
comedication(s) that could
increase statin exposurec
77 (11%) 7 (16%) 31 (12%) 29 (10%) 0 (0%) 3 (7%) 7 (12%) 0.665
Participants takingR1
comedication(s) that could
decrease statin exposurec
7 (1%) 1 (2%) 2 (1%) 2 (1%) 0 (0%) 1 (2%) 1 (2%) 0.333
GATM, gene encoding glycine amidinotransferase; SIM, statin-induced myopathy.
aContinuous variables are presented asmedian (interquartile range) and compared with the Kruskal-Wallis test. Categorical variables are presented as
counts (%) and compared with the chi-square or Fisher’s exact test where necessary. p values are for the comparison of all groups stratified byGATM
rs9806699 genotype and SIM status. Italicized values are for p < 0.05.
bAtorvastatin dose equivalents were calculated as follows: fluvastatin dose/8, lovastatin dose/4, pravastatin dose/4, rosuvastatin dose*4, and simva-
statin dose/2 (Stone et al., 2014). Dose equivalents were missing for cerivastatin (n = 6) and pitavastatin (n = 1).
cCategories of potentially confounding comedications are defined in the Supplemental Experimental Procedures.
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Table 2. GATM rs9806699 Minor Allele and Genotype
Frequencies in the Controls, Mild SIM Cases, and Severe SIM
Cases
All Subjects (n = 715)
Control
(n = 106)
Mild SIM
(n = 324)
Severe SIM
(n = 285) p Value
MAF (A) 0.26 0.28 0.29 0.447
A/A 0.07 0.08 0.06 0.436
G/A 0.39 0.40 0.47
G/G 0.55 0.52 0.48
Subjects without Confounding Comedications (n = 386)
Control
(n = 80)
Mild SIM
(n = 165)
Severe SIM
(n = 141)
P Value
MAF (A) 0.28 0.26 0.25 0.605
A/A 0.09 0.07 0.04 0.598
G/A 0.38 0.39 0.43
G/G 0.54 0.55 0.54
Propensity-Matched Data Set (n = 188)
Control
(n = 94)
Mild SIM
(n = 44)
Severe SIM
(n = 50)
P Value
MAF (A) 0.26 0.31 0.28 0.489
A/A 0.07 0.07 0.04 0.475
G/A 0.37 0.48 0.48
G/G 0.55 0.45 0.48
MAF, minor allele frequency; SIM, statin-induced myopathy.definition of SIM has been established (Rosenson et al., 2014).
The subjective (muscle complaints) and objective (biochemical
markers) measures delineating SIM vary significantly among
studies (Rosenson et al., 2014). Mangravite et al. (2013) defined
cases of SIM as patients with muscle symptoms and serum CK
concentrations >3 times the upper limit of normal (xULN) and
>103ULN. In contrast, our study did not use CK in the definition
of SIM, because only 34% of the combined mild and severe SIM
participants in this retrospective study reported measurement
of CK. Arguably, the absence of CK data in our definition of
SIM may be a limitation; however, Mangravite et al. (2013) did
not find an association between GATM rs9806699 and CK
concentrations, and CK does not routinely correlate with the
presence or severity of muscle symptoms. Furthermore, the
current cholesterol treatment guidelines by the American
College of Cardiology and the American Heart Association
recommend monitoring CK levels only after severe muscle
symptoms occur. Monitoring CK levels is not performed for the
purpose of establishing a diagnosis of SIM but for identifying
the presence of rhabdomyolysis (Stone et al., 2014). We argue
that any muscle effect severe enough to trigger a decrease or
discontinuation of statin therapy is clinically relevant; muscle
symptoms in the absence of CK elevations have been docu-
mented (Phillips et al., 2002).
Lack of reproducibility in biomedical research is being increas-
ingly recognized as a major problem (Collins and Tabak, 2014).
This is troubling for the research community because it can
cause stakeholders, such as patients, clinicians, policymakers,
and funding agencies, to lose confidence in biomedical
research. Further investigation of potential reasons for theCrepeated failed replication of the findings by Mangravite et al.
(2013) is warranted. The study reported by Mangravite et al.
(2013) was robust and of the highest quality: a combination of
functional in vitro findings translated to two independent clinical
studies. Therefore a false-positive finding by Mangravite et al.
(2013) is highly unlikely. Alternatively, false null findings by our
group, Carr et al. (2014), and Floyd et al. (2014) are also highly un-
likely because the association failed replication in three separate
clinical studies performed by three independent research
groups. A key piece of information that may solve this apparent
contradiction is the mechanism by which GATM variation im-
pacts SIM; currently the mechanism can only be hypothesized.
Experiments establishing the mechanism of GATM involvement
with SIM are necessary and could shed light on the specific con-
ditions, if any, in which GATM affects SIM. If a clear mechanism
cannot be established, then the findings by Mangravite et al.
(2013) could have been another case of the ‘‘winner’s curse.’’
The ‘‘winner’s curse’’ is a common phenomenon in genetic asso-
ciation literature, in which the initial reported genotype–pheno-
type association is exaggerated relative to the estimated effect
in follow-up studies or cannot subsequently be replicated at all
(Talameh and McLeod, 2011; Zollner and Pritchard, 2007).
Notably, our study has certain limitations. The proportion of
controls (15%) was small compared to SIM cases (85%). How-
ever, we balanced the sample sizes and characteristics of the
cases and control using propensity matching and still found a
null association. Controls were defined as participants without
myopathic symptoms after 6 months of statin therapy and moni-
tored for any change in status by questionnaire at 12 months.
However, it is possible for the onset of SIM to occur even after
12 months of statin therapy. SIM is exacerbated by exercise
(Parker and Thompson, 2012), but exercise was not assessed
in this study. Two other polymorphisms in GATM (rs1719247
and rs1346268) remained statistically significant in a fixed-ef-
fects meta-analysis byMangravite et al. (2014) for an association
with SIM, but only rs9806699 was genotyped in our study. Using
1,000 Genomes CEU data, the extent of linkage disequilibrium
for both rs1719247 and rs1346268 with rs9806699 is r2 = 0.85
and D0 = 1.0. Notably, Floyd et al. (2014) also performed fixed-
effects meta-analyses for rs1719247 and rs1346268, but they
found null associations.
In conclusion, we provide further evidence against an associ-
ation between GATM rs9806699 and SIM in a large, multicenter
case-control study of both mild and severe SIM in Caucasian
participants. Experiments elucidating the potential mechanism
betweenGATM and SIM are necessary to determine the specific
conditions, if any, under which GATM may truly affect SIM.EXPERIMENTAL PROCEDURES
Participants
Cases and controls (n = 836) were derived from six medical centers in six
states and provinces in the United States and in Canada representative of
no single geographic location. Data for all participants were collected via a
standardized questionnaire administered by a research coordinator. The prin-
cipal investigator, Dr. Georgirene D. Vladutiu, reviewed every questionnaire
and individually telephoned every case that had gaps of information or incon-
sistencies. (This communication was documented.) We have previously re-
ported our definition of mild versus severe SIM (Vladutiu et al., 2011). Briefly,
mildly affected cases were defined as participants with muscle aches andell Metabolism 21, 622–627, April 7, 2015 ª2015 Elsevier Inc. 625
Table 3. Logistic Regression Modeling Results
All Subjects (n = 715)
Model Outcome Covariates Odds Ratio 95% CI p Value
1 control versus SIM (mild and severe) None 1.14 (0.82–1.61) 0.437
2 control versus SIM (mild and severe) age + sex 1.17 (0.78–1.77) 0.447
4 control versus mild SIM only None 1.11 (0.79–1.58) 0.548
5 control versus mild SIM only age + sex 1.15 (0.75–1.77) 0.517
6 control versus severe SIM only None 1.18 (0.81–1.72) 0.382
7 control versus severe SIM only age + sex 1.19 (0.76–1.85) 0.453
Subjects without Potentially Confounding Medications (n = 386)
Model Outcome Covariates Odds Ratio 95% CI p Value
8 control versus SIM (mild and severe) None 0.90 (0.60–1.34) 0.598
9 control versus SIM (mild and severe) age + sex 1.00 (0.61–1.62) 0.982
11 control versus mild SIM only None 0.93 (0.61–1.42) 0.737
12 control versus mild SIM only age + sex 1.06 (0.63–1.77) 0.833
13 control versus severe SIM only None 0.86 (0.55–1.36) 0.523
14 control versus severe SIM only age + sex 0.91 (0.53–1.57) 0.740
Propensity-Matched Data Set (n = 188)
Model Outcome Covariates Odds Ratio 95% CI p Value
15 control versus SIM (mild and severe) None 1.19 (0.74–1.90) 0.475
16 control versus SIM (mild and severe) age + sex 1.33 (0.75–2.36) 0.338
17 control versus mild SIM only None 1.23 (0.70–2.16) 0.482
18 control versus mild SIM only age + sex 1.70 (0.80–3.60) 0.170
19 control versus severe SIM only None 1.08 (0.61–1.88) 0.800
20 control versus severe SIM only age + sex 1.17 (0.60–2.28) 0.648
CI, confidence interval; SIM, statin-induced myopathy.pains associated with the initiation of statin therapy that were reversible
with cessation of therapy. Severely affected cases experienced symptoms
of incapacitating muscle pain with or without weakness or with weakness
alone that led to rhabdomyolysis in a number of cases and serum CK > 4 3
ULN in 50% of cases in which it was quantified. Approximately 79% of partic-
ipants continued to have severe symptoms forR6months following discontin-
uation of statin therapy, and 24% experienced progressive worsening with0.25 0.50 0.75 1.00 1.25 1.50 1.75
Mangravite et al (2013) Marshfield
Carr et al (2014)
Floyd et al (2014) 
Luzum et al (2015)
Combined
Odds ratio
Figure 1. Forest Plot of Odds Ratios and 95% Confidence Intervals
from Individual Studies of the Association between GATM
rs9806699 and SIM and the Combined Results from the Fixed-Effect
Meta-analysis
Data excluding fibrate users (Mangravite et al. [2013] Marshfield cohort and
Floyd et al. [2014]) and any potentially interacting medications were used,
except for the data from Carr et al. (2014) because concomitant medication
information was not available. The 95% confidence intervals from the Carr
et al. (2014) study were also not available, and thus they were estimated using
the standard error from our data (lowest standard error of all studies).
626 Cell Metabolism 21, 622–627, April 7, 2015 ª2015 Elsevier Inc.time. The time of onset of symptoms may have varied, but the association
with statin therapy must have been clear to the referring physician and the
participants themselves. Age- and gender-matched controls were recruited
at collaborating centers following at least 6 months of statin therapy without
myopathic symptoms. They were also monitored, via questionnaire, for
change in status at 12months. Details on the data collection and comedication
classifications can be found in the Supplemental Experimental Procedures.
The study was approved by the institutional review boards at each study
site, and all participants provided written informed consent.
Genotyping
Genomic DNA was prepared from whole blood collected in EDTA tubes with
Gentra Puregene DNA isolation kits (QIAGEN, Valencia, CA, USA). Genotypes
for GATM rs9806699 were obtained using a TaqMan genotyping assay
(C__30104701_10; Life Technologies, NY, USA) and analyzed with a MJR
Opticon 2 real-time detection system (Bio-Rad, Hercules, CA, USA).
Statistical Methods
Continuous variables were summarized as median and interquartile range and
compared using the Kruskal-Wallis test. Categorical variables were summa-
rized as counts and percentages and compared using chi-square or Fisher’s
exact test where necessary. The Monte Carlo estimate of the exact p value
for Hardy-Weinberg equilibrium (HWE) was calculated in the Caucasian sub-
jects using 10,000 permutations. Genetic associations were evaluated by
both allele- and genotype-based tests. The primary analysis was for the asso-
ciation with any SIM (mild or severe), and the secondary analyses assessed
the associations with mild SIM alone and severe SIM alone. Univariate and
age- and sex-adjusted logistic regression models were used. Sensitivity ana-
lyseswere performed in a subgroup of participants (n = 386) without potentially
confounding comedications (defined in Supplemental Experimental Proce-
dures) and a propensity-matched data set. The purpose of propensity match-
ing was to eliminate the known differences in the characteristics and sample
sizes between the cases and controls. The propensity-matched data set
matched control subjects with SIM (mild or severe) subjects 1:1 using a greedy
8/1 matching algorithm (Parsons, 2004; Rosenbaum and Rubin, 1983;
D’Agostino, 1998). Cases and controls were matched based on the signifi-
cantly different characteristics in Table 1 (statin therapy, coronary artery dis-
ease, hypertension, smoking status, family history of heart disease, obesity,
and comedications that could treat SIM). A fixed-effect meta-analysis of all
studies evaluating the association between rs9806699 and SIM (Table S2)
was performed (Senn et al., 2011). Data excluding fibrate users (Mangravite
et al. [2013] Marshfield cohort and Floyd et al. [2014]) and any potentially inter-
acting medications were used, except for the data from Carr et al. (2014)
because concomitant medication information was not available. The 95%
confidence intervals from the Carr et al. (2014) study were also not available,
and thus they were estimated using the standard error from our data (lowest
standard error of all studies). All statistical analyses were performed using
SAS version 9.3 (Cary, NC, USA). p < 0.05 was considered statistically
significant.
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